Clinical efficacy of antibacterial drugs combined with Proton Pump Inhibitors and Bismuth in the treatment of Helicobacter Pylori-infected Peptic Ulcer.

OBJECTIVE

To investigate the clinical efficacy of antibacterial drugs combined with proton pump inhibitors and bismuth in the treatment of Helicobacter pylori (Hp)-infected peptic ulcer.

METHODOLOGY: This was a retrospective study. A total of 116 patients with Hp-infected peptic ulcer treated at Cangzhou People's Hospital from January 2023 to December 2024 were selected as study subjects and randomly divided into an observation group(n=58) treated with antibacterial drugs in addition to the treatment for the control group and a control group(n=58) received proton pump inhibitors and bismuth using the computer-based lottery method. The clinical efficacy, time to symptom subsidence treatment safety were assessed and compared between the two groups.

RESULTS

The overall response rate of the observation group was higher than that of the control group(P<0.05). Specifically, the time to symptom subsidence in the observation group was shorter than that in the control group(P<0.05), and the post-treatment levels of G-17, PGI and PGII in the observation group were lower than those in the control group(P< 0.05). Meanwhile, the post-treatment serum levels of GAS, VIP, and MOT in the observation group were higher than those in the control group(P<0.05). Additionally, the observation group reported lower post-treatment serum levels of TRX-1, TRAF1, and MMP-9 than the control group(P<0.05), with no significant differences observed in the incidence of adverse reactions between the two groups(P>0.05).

CONCLUSION

Antibacterial drugs combined with proton pump inhibitors and bismuth are remarkably effective in treating Hp-infected peptic ulcer, which promotes the subsidence of symptoms, improves gastric function, increases gastrointestinal hormone levels.